The Role of FGF23 and Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by Ankara Education and Research Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Ankara Education and Research Hospital
ClinicalTrials.gov Identifier:
NCT01317186
First received: March 16, 2011
Last updated: NA
Last verified: March 2011
History: No changes posted
  Purpose

In chronic kidney disease calcium (Ca) and phosphate (P) metabolism disorders are very common and also they are one of the leading causes of morbidity in these population. FGF23 is a novel factor that contributes Ca-P disorders. It has been hypothesized that FGF 23 increase is mediated by asymmetric dimethylarginine (ADMA). The aim of the study is to evaluate this hypothesis.


Condition
Metabolic Diseases
Chronic Kidney Disease

Study Type: Observational
Study Design: Observational Model: Cohort

Resource links provided by NLM:


Further study details as provided by Ankara Education and Research Hospital:

Estimated Enrollment: 100
Study Start Date: March 2011
Groups/Cohorts
Group I
Stage 2 Non-diabetic Chronic Kidney Disease
Group II
Stage 3 Non-diabetic Chronic Kidney Disease
Group III
Stage 4 Non-diabetic Chronic Kidney Disease

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Stage 2-4 Non-diabetic Chronic Kidney Disease patients

Criteria

Inclusion Criteria:

  • between ages of 18 - 65 years old
  • chronic kidney disease of stage 2-4

Exclusion Criteria:

  • presence of diabetes mellitus or ischemic hearth disease
  • taking vitamin d therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01317186

Locations
Turkey
Ankara Education and Research Hospital Recruiting
Ankara, Turkey
Contact: Alper AZAK       dralperazak@gmail.com   
Contact: Bülent Huddam       drhuddam@yahoo.com   
Sub-Investigator: Bülent Huddam         
Sponsors and Collaborators
Ankara Education and Research Hospital
  More Information

No publications provided

Responsible Party: Bülent Huddam, Ankara Education and Research Hospital
ClinicalTrials.gov Identifier: NCT01317186     History of Changes
Other Study ID Numbers: NEPH002
Study First Received: March 16, 2011
Last Updated: March 16, 2011
Health Authority: Turkey: Ethics Committee

Keywords provided by Ankara Education and Research Hospital:
FGF 23
ADMA
chronic kidney disease
Ca-P metabolism disorder

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Metabolic Diseases
Urologic Diseases
Renal Insufficiency
N,N-dimethylarginine
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 30, 2014